# TEFLARO — FDA application NDA200327

Informational only - not investment advice.

Application NDA200327 · type NDA · FDA status: approved · original approval 2010-10-29

Listed sponsor: ABBVIE · [ABBV company profile](/company/ABBV/) · exact_unique

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

## FDA application facts

| Product | FDA-listed trade name | Active ingredient | Dosage form | Route | Strength | Marketing status | TE code | RLD |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 001 | TEFLARO | CEFTAROLINE FOSAMIL | POWDER | INTRAVENOUS | 400MG/VIAL | Prescription | AP | Yes |
| 002 | TEFLARO | CEFTAROLINE FOSAMIL | POWDER | INTRAVENOUS | 600MG/VIAL | Prescription | AP | Yes |

## Orange Book patent and exclusivity listings

- Patent 9629861, product 001; listed patent expiry date: 2030-09-21.
- Patent 9629861, product 002; listed patent expiry date: 2030-09-21.
- Patent 8247400, product 001; listed patent expiry date: 2031-02-10.
- Patent 8247400, product 002; listed patent expiry date: 2031-02-10.

Patent and exclusivity dates are regulatory listings from the FDA Orange Book; no relationship to revenue or future sales is stated or implied.

## Compound cross-links

- CEFTAROLINE FOSAMIL · UNII 7P6FQA5D21 · [lmmol compound ZCCUWMICIWSJIX-NQJJCJBVSA-N](https://lmmol.com/compound/ZCCUWMICIWSJIX-NQJJCJBVSA-N)

Ingredient–compound links use FDA openFDA/GSRS identifiers and an exact lmmol InChIKey join. Ingredient names cannot create a link.

## Related pages

- [Sponsor company](/company/ABBV/)
- [FDA-approved application index](/drug/)
- [Large-cap biopharma](/compare/pharma/)

Sources: https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files · https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files · https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA200327. FDA data retrieved 2026-08-07.

Regulatory listing data as published by FDA; not medical or investment advice.